Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175456 | 0.82 | CCNT1 (0.40) | CCNT1PTPRCL3MBTL1VSIREPHX2 | |
| SCHEMBL6178813 | 0.80 | RAB9A (0.50) | CCNT1SMN1; SMN2 | |
| SCHEMBL6697790 | 0.76 | CCNT1 (0.42) | CCNT1HSD11B1VSIR | |
| SCHEMBL4846482 | 0.76 | PTGER2 (0.46) | CCNT1 | |
| SCHEMBL7040751 | 0.75 | CACNA1C (0.46) | HSD11B1SMN1; SMN2 | |
| SCHEMBL6720555 | 0.74 | CCNT1 (0.41) | CCNT1SMN1; SMN2VSIR | |
| SCHEMBL3108921 | 0.74 | CYP1A2 (0.57) | CCNT1L3MBTL1SMN1; SMN2 | |
| SCHEMBL854260 | 0.73 | CCNT1 (0.43) | CCNT1HSD11B1L3MBTL1SMN1; SMN2 | |
| SCHEMBL966489 | 0.73 | SMN1; SMN2 (0.44) | HSD11B1L3MBTL1SMN1; SMN2 | |
| Acetic Acid SCHEMBL4671431 | 0.71 | FABP1 (0.43) | CCNT1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1218005-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1218005-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1218005-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017959-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | CCNT1 1964/4885PTPRC 1567/4885HSD11B1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.